The risk or severity of adverse effects can be increased when Ibuprofen is combined with Equilenin. The serum concentration of Tixocortol can be increased when it is combined with Lopinavir. The risk or severity of adverse effects can be increased when Umeclidinium is combined with Buprenorphine. The metabolism of Trimethoprim can be decreased when combined with Lapatinib. The metabolism of Ketoprofen can be decreased when combined with Irbesartan. The serum concentration of Desipramine can be increased when it is combined with Linagliptin. The serum concentration of Theophylline can be decreased when it is combined with Linagliptin. Doxepin may increase the QTc-prolonging activities of Quinidine. The serum concentration of Eletriptan can be increased when it is combined with Verapamil. Becaplermin may increase the anticoagulant activities of Fluindione. Vilanterol may increase the hypokalemic activities of Methyclothiazide. The metabolism of Ketoprofen can be decreased when combined with Delavirdine. Vardenafil may increase the antihypertensive activities of Pargyline. The metabolism of Elvitegravir can be decreased when combined with Verapamil. The serum concentration of Gliquidone can be increased when it is combined with Cimetidine. Neamine may increase the hypocalcemic activities of Etidronic acid. Erythromycin may increase the QTc-prolonging activities of Haloperidol. The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Simvastatin. Piroxicam may increase the anticoagulant activities of Citric Acid. Antipyrine may decrease the excretion rate of Tobramycin which could result in a higher serum level. The metabolism of Cabazitaxel can be decreased when combined with Pioglitazone. Methoxsalen may increase the photosensitizing activities of Verteporfin. Nebivolol may increase the bradycardic activities of Midodrine. Pivhydrazine may increase the hypotensive activities of Perindopril. The therapeutic efficacy of Indapamide can be decreased when used in combination with Carbaspirin calcium. The serum concentration of Pralatrexate can be increased when it is combined with Oxyphenbutazone. The serum concentration of Fosamprenavir can be increased when it is combined with Simeprevir. The serum concentration of Atorvastatin can be decreased when it is combined with Dabrafenib. The metabolism of 4-Methoxyamphetamine can be decreased when combined with Ritonavir. The risk or severity of adverse effects can be increased when Ritanserin is combined with Clonidine. The risk or severity of adverse effects can be increased when Amobarbital is combined with Osanetant. Propoxycaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. Prednicarbate may increase the hypokalemic activities of Indapamide. The metabolism of Valsartan can be decreased when combined with Ketoconazole. The serum concentration of Flumethasone can be increased when it is combined with Lopinavir. The risk or severity of adverse effects can be increased when Losartan is combined with Pindolol. The metabolism of Phenacetin can be decreased when combined with Cyclosporine. The metabolism of Zaleplon can be decreased when combined with Dihydroergotamine. The metabolism of Levomilnacipran can be decreased when combined with Clemastine. The risk or severity of adverse effects can be increased when Tenoxicam is combined with Etidronic acid. The risk or severity of adverse effects can be increased when Streptokinase is combined with Valsartan. The serum concentration of Buprenorphine can be decreased when it is combined with Rilpivirine. Niflumic Acid may decrease the antihypertensive activities of Pindolol. The serum concentration of Diethylstilbestrol can be decreased when it is combined with Elafin. The metabolism of Amlodipine can be decreased when combined with Saquinavir. Labetalol may increase the hypotensive activities of Tolazoline. The metabolism of Antipyrine can be decreased when combined with Azithromycin. The serum concentration of Losartan can be increased when it is combined with Ceritinib. The risk or severity of adverse effects can be increased when Triazolam is combined with Meclizine. Lisdexamfetamine may decrease the sedative activities of Cinnarizine. Nebivolol may increase the hypoglycemic activities of Gliclazide. The risk or severity of adverse effects can be increased when Quinapril is combined with Guanfacine. The serum concentration of Retapamulin can be increased when it is combined with Darunavir. The risk or severity of adverse effects can be increased when Benzydamine is combined with Oleoyl-estrone. The serum concentration of Ketoconazole can be increased when it is combined with Darunavir. The metabolism of Vardenafil can be decreased when combined with Clemastine. The serum concentration of Doxorubicin can be increased when it is combined with Verapamil. The serum concentration of Paritaprevir can be increased when it is combined with Atazanavir. Alprenolol may increase the hypotensive activities of Metipranolol. The metabolism of Tiotropium can be decreased when combined with Nefazodone. The risk or severity of adverse effects can be increased when Conivaptan is combined with Chlorothiazide. The risk or severity of adverse effects can be increased when Ketorolac is combined with Fluocinolone Acetonide. The serum concentration of Dexamethasone can be increased when it is combined with Simeprevir. The bioavailability of Fluticasone propionate can be decreased when combined with Magnesium oxide. The risk or severity of adverse effects can be increased when Lofexidine is combined with Tamsulosin. Magnesium Hydroxide may increase the neuromuscular blocking activities of Vecuronium. The serum concentration of Desoximetasone can be decreased when it is combined with Pentobarbital. The serum concentration of Artemether can be increased when it is combined with Ivacaftor. The serum concentration of Dofetilide can be increased when it is combined with Fusidic Acid. The serum concentration of Rosuvastatin can be increased when it is combined with Hydralazine. The serum concentration of Dyphylline can be decreased when it is combined with Secobarbital. The risk or severity of adverse effects can be increased when Antipyrine is combined with Methylprednisolone. Meloxicam may decrease the antihypertensive activities of Bevantolol. The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Tacrolimus. Fenoldopam may increase the hypotensive activities of Oxprenolol. The risk or severity of adverse effects can be increased when Streptokinase is combined with Indapamide. The risk or severity of adverse effects can be increased when Losartan is combined with Enalaprilat. The risk or severity of adverse effects can be increased when Scopolamine is combined with Solifenacin. The serum concentration of Telaprevir can be decreased when it is combined with Mometasone. The risk or severity of adverse effects can be increased when Desoximetasone is combined with Huperzine A. The risk or severity of adverse effects can be increased when Ethosuximide is combined with Cyclizine. Digoxin may decrease the cardiotoxic activities of Moxifloxacin. The metabolism of Sunitinib can be decreased when combined with Verapamil. The serum concentration of Sofosbuvir can be decreased when it is combined with Clotrimazole. Methaqualone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. The risk or severity of adverse effects can be increased when Metronidazole is combined with Tipranavir. The risk or severity of adverse effects can be increased when Piritramide is combined with Polythiazide. The serum concentration of Estrone sulfate can be decreased when it is combined with Moexipril. The risk or severity of adverse effects can be increased when Omapatrilat is combined with Ketorolac. Udenafil may increase the vasodilatory activities of Erythrityl Tetranitrate. The serum concentration of Zomepirac can be increased when it is combined with Simeprevir. Oxprenolol may decrease the bronchodilatory activities of Indacaterol. The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Tixocortol. Oxymetholone may increase the hypoglycemic activities of Saxagliptin. Magnesium oxide can cause a decrease in the absorption of Chlortetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy. The risk or severity of adverse effects can be increased when Propantheline is combined with Diphenoxylate. Azelastine may increase the sedative activities of Metyrosine. Minocycline may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine. Solifenacin may increase the tachycardic activities of Nabilone. The therapeutic efficacy of Insulin Human can be decreased when used in combination with Articaine. Hydroflumethiazide may increase the hypotensive activities of Niguldipine. Silodosin may decrease the vasoconstricting activities of Pirbuterol. The metabolism of Donepezil can be decreased when combined with Artemether. The serum concentration of Sildenafil can be decreased when it is combined with Cyproterone acetate. Indapamide may increase the hypotensive activities of Phenoxybenzamine. The metabolism of Cyclosporine can be decreased when combined with Verapamil. The serum concentration of Rosuvastatin can be decreased when it is combined with Dabrafenib. The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Trichlormethiazide. The metabolism of Atomoxetine can be decreased when combined with Clotrimazole. The metabolism of Lisuride can be decreased when combined with Rucaparib. The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Ketobemidone. The metabolism of Dexmethylphenidate can be decreased when combined with Cocaine. The serum concentration of Meprobamate can be decreased when it is combined with Cyproterone acetate. Piroxicam may decrease the excretion rate of Neamine which could result in a higher serum level. The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Tolmetin. The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Mometasone. Meloxicam may decrease the antihypertensive activities of Metipranolol. Etorphine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. The serum concentration of Pilocarpine can be increased when it is combined with Osimertinib. The serum concentration of Flurandrenolide can be decreased when it is combined with St. John's Wort. The metabolism of Ketobemidone can be decreased when combined with Teriflunomide. The serum concentration of Rosuvastatin can be increased when it is combined with Ramipril. The serum concentration of Loteprednol can be increased when it is combined with Darunavir. The risk or severity of adverse effects can be increased when Sevoflurane is combined with Cocaine. Tolmetin may decrease the antihypertensive activities of Timolol. Trichlormethiazide may increase the hypercalcemic activities of Paricalcitol. Amoxapine may increase the QTc-prolonging activities of Moxifloxacin. Thiopental may increase the hypotensive activities of Benazepril. The serum concentration of Trichlormethiazide can be increased when it is combined with Orphenadrine. The serum concentration of Dihydrocodeine can be decreased when it is combined with Rilpivirine.